VEGFA and neoplasm: VEGF blockade using specific antibodies against VEGF or VEGFR2 increased high endothelial venules (HEVs) in the TME and enhanced both cytotoxic CD8(+) and helper CD4(+) cell traffic into TME by up to 8-fold, resulting in improved anti-tumor effects against NB xenografts.